Role of radiothearapy in managment of oligometastatic prastate cancer
Answers
Radiation therapy is a well-established curative therapy for intact localized and postoperative locally recurrent prostate cancer, and an effective palliative therapy for symptomatic metastatic disease. Conversely, its role in oligometastatic disease in an effort to improve survival is unknown.
Dachuti2426, don't be offended but I do not understand how you can understand the answer when the spelling of prostrate cancer is wrong. You have written it as prastate.
Still, here you go and if you have any further explicit doubt regarding any term or phrases, you can ask...
Advances in clinical and molecular imaging techniques have led to the recognition of an intermediate state of prostate cancer (PCa) in which the disease has extended beyond the prostate, although with limited spread to distant organs.
Further research focusing on micro-RNAs involved in the development of metastatic disease has shown distinct regulation processes between oligometastatic and polymetastatic patients, suggesting that they are distinct disease entities rather than different points in a continuous evolution.
Also, metastatic cell clones have suggested that the lethal clone may originate from the metastatic lesion, and not from the primary tumor.
Thus, oligometastatic disease can be considered a heterogeneous disease entity with distinct metastatic phenotypes, which may have different prognoses. The clinical implication of this hypothesis is that definitive directed treatments for oligometastatic PCa, including radical prostatectomy (RP), radiation therapy (RT), and metastasis-directed surgery or ablative therapy, may be utilized for selected patients with a curative intent.
This may improve survival for selected patients with metastatic PCa.
Research is ongoing to distinguish subsets of patients who may benefit from aggressive treatment.
The curative treatment of oligometastatic PCa requires a three-tiered approach: 1) local consolidative therapy of the primary tumor, 2) metastasis-directed therapy, and 3) systemic chemohormonal therapy.10 To date, there is no definite evidence-based guideline on the role of these treatments for oligometastatic PCa.